Background {#Sec1}
==========

Systemic Juvenile Idiopathic Arthritis (JIA) is a rare childhood inflammatory disease associated with significant morbidity, and characterized by arthritis accompanied by high spiking fevers, plus additional features such as rash, generalized lymphadenopathy, hepatosplenomegaly, and serositis \[[@CR1]\]. There is considerable variation in systemic JIA treatment, due in part to a heterogeneous and somewhat unpredictable disease course, differences in physician practices, and until very recently, a lack of clinical trial data \[[@CR2]--[@CR5]\] and evidence based guidelines \[[@CR6], [@CR7]\]. Recent trials of IL-1 and IL-6 inhibitors (IL1i and IL6i) which demonstrated striking efficacy in systemic JIA were conducted in children with established chronic disease, so little evidence exists for use of biologic agents in new-onset or untreated systemic JIA. Nevertheless, many pediatric rheumatologists currently treat with IL1i and/or IL6i early in the course of disease \[[@CR8]--[@CR10]\]. Intriguing data from several uncontrolled case series suggest that early use of these biologic agents might favorably alter the potentially devastating outcomes of chronic persistent systemic JIA \[[@CR10], [@CR11]\]. On the other hand, as many as 10--40% of patients may have a monocyclic course which remits spontaneously within the first year \[[@CR12], [@CR13]\], complicating the evaluation of treatment effectiveness in early disease. An additional consideration is the question of whether rare, potentially fatal cardiopulmonary complications may be associated with the increased use of these agents specifically in systemic JIA \[[@CR14]\].

With new options for treatment now commercially available and FDA approved, there is an urgent need to determine the relative effectiveness, safety and tolerability of commonly used treatments in systemic JIA. While a blinded randomized multi-arm controlled clinical trial would be ideal, it would be cost-prohibitive, require a very large sample size and likely not be feasible to perform in such a rare disease of childhood. Comparative effectiveness research (CER) studies in an observational, routine care setting are therefore a more practical approach to examine which treatments are effective and most appropriate for an individual child \[[@CR15], [@CR16]\]. In such a study, physician choice (together with patient/caregiver preferences) would be the primary determining factor for treatment selection. Such a study could be successful if there were equipoise between most common treatments and if the treatments and data collection were standardized and captured at predetermined intervals. The development of Consensus-derived standardized Treatment Plans (CTPs) for systemic JIA funded by a National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Challenge Grant (1RC1AR058605-01) to the Childhood Arthritis and Rheumatology Research Alliance (CARRA) was a key step in this process and in improving outcomes for patients with systemic JIA \[[@CR17], [@CR18]\]. The methods by which the CARRA CTPs were developed using CARRA-wide surveys to identify the current most commonly used treatments for systemic JIA and the standardization process using consensus methodology are outlined in a previously published article \[[@CR17]\].

A pilot study comparing the published CARRA systemic JIA CTPs was funded by an Arthritis Foundation Innovative Research Grant and conducted in a limited number of sites in order to test the acceptance and usability of these CTPs in preparation for a future large comparative effectiveness study that would utilize the broader CARRA Registry network. This pilot study was conducted to assess the feasibility of conducting a larger more definitive CER study and to identify possible issues that could arise in such a study \[[@CR19]\].

Methods {#Sec2}
=======

Patients were enrolled in the CARRA Registry and treated with one of the systemic JIA CTPs at 13 CARRA Registry sites for 9 months during the period from 2011 to 2014. Funding from NIAMS via the American Recovery and Reinvestment Act (ARRA) in 2010 enabled the CARRA Registry, a multi-center prospective observational study of children with pediatric rheumatic diseases including JIA. Altogether, investigators enrolled over 9,500 patients in what is now called the CARRA Legacy Registry, including more than 7,000 with JIA (\>500 with systemic JIA) at 60 sites over 3 years \[[@CR9]\]. The CARRA Registry general protocol and consent was approved by the Duke University IRB (\#Pro00054616) and at all participating site IRBs. Because the CTP study is not interventional and patients received standard-of-care therapy at the discretion of their treating physician, additional consent for participation beyond this standard consent for the CARRA Registry was not required.

The entry criteria used were a CARRA-modified version of the International League of Associations of Rheumatology (ILAR) criteria \[[@CR20]\], as published in the original article describing the development of the systemic JIA CTPs \[[@CR17]\]. In order to capture as many children with systemic JIA as possible while avoiding inclusion of children with self-limited febrile illnesses or alternative diagnoses, it was decided by consensus of the pediatric rheumatologists in the CARRA JIA Research Committee to adapt the ILAR criteria for new-onset patients. The modifications were to require at least 2 weeks of fever (but not necessarily on continuous days), at least one joint with physician-documented arthritis for at least a week, along with at least one other ILAR systemic JIA feature. No prior treatment for systemic JIA aside from NSAIDs or short-term (less than 2 weeks) GC were allowed. There was no randomization or blinding of treatment assignment; instead, a CTP was chosen for each child by the treating pediatric rheumatologist after discussion with the child and family as part of customary clinical decision making process. The CTP choices were: (1) GC only; (2) Methotrexate ± GC; (3) IL1i (either anakinra or canakinumab) ± GC \[[@CR18]\]; and (4) IL6i (tocilizumab) ± GC.

Follow-up visits occurred at intervals defined by the CTPs and consistent with routine care: 2 weeks, 1, 3, 6 and 9 months after baseline. Unscheduled visits were conducted if there was a change in CTP medication. Clinical and laboratory data, determined previously by consensus-based process and also consistent with routine care, were collected at these time points through the CARRA Registry as outlined in the CTPs \[[@CR17]\]. The CTPs recommended that if patients worsened or failed to improve sufficiently as determined by the physician's assessment of disease activity, GC could be added or increased, or the treatment (CTP) changed. Suggested GC tapering schedules corresponding to very rapid, rapid, moderate, and slow tapering schedules were provided to be used by the treating physician but were not compulsory. By 3 months after CTP initiation, if the child was still receiving ≥50% of the starting dose of GC, it was recommended that the treatment (CTP) should be changed anticipating a better outcome. The treating physicians were asked why a particular initial CTP was chosen, and to provide the reason if the treating CTP was changed. Serious adverse events, including macrophage activation syndrome (MAS), and side effects of medications, were collected.

Outcomes included the primary endpoint of the study: clinical inactive disease (CID) off glucocorticoids at 9 months. CID was defined using the ACR provisional criteria for defining clinical inactive disease which specifies all the following: no active arthritis, a physician's global assessment of disease activity score of 0, ESR and/or CRP in the normal range, no features of systemic JIA (fever, rash, serositis, splenomegaly, or generalized lymphadenopathy), no uveitis and duration of morning stiffness for \<15 min \[[@CR21]\]. All inactive disease criteria \[[@CR22]\] were available for all children who had a documented 9 month visit. For the primary endpoint analysis, all patients were included even if lost to follow-up. The GC and methotrexate CTP-initiated patients were combined as the non-biologic CTP group, while the IL1i and IL6i CTP initiated patients were combined as the biologic CTP group. Secondarily, all 4 CTPs were analyzed separately assessing achievement of the primary endpoint, as well as the ability to lower GC doses.

Safety assessments included reporting of serious adverse events (SAEs), defined as an adverse event that results in death, is life-threatening, requires hospitalization or prolongation of a hospitalization, persistent or significant disability or in capacity, or a congenital anomaly or birth defect; and adverse events (AEs). AEs were graded using Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 1 AE was asymptomatic or with mild symptoms and required either clinical or diagnostic observations or no intervention. Grade 2 AE was defined as moderate severity requiring minimal, local or noninvasive intervention. Grade 3 was a severe or medically significant event but not immediately life-threatening and either hospitalization or prolongation of hospitalization were required. Grade 4 AEs were defined as those with life-threatening consequences or requiring urgent intervention. The MedDRA dictionary was not used for safety reporting in this pilot study.

Differences in data collected from the CTPs were compared using chi square, Fisher's exact, and Wilcoxon rank sum tests.

Results {#Sec3}
=======

Thirty untreated, mostly newly diagnosed systemic JIA patients were enrolled into the CARRA Registry at 13 sites and started on a CARRA systemic JIA CTP. The children's clinical and demographic characteristics are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Baseline demographic and disease characteristics in all systemic JIA CTP patientsGC (*N* = 2)MTX (*N* = 6)IL1 Inhibitor (*N* = 12)IL6 Inhibitor (*N* = 10)Total (*N* = 30)*P*-valueAge in years^a^12.83.44.09.85.70.047Female50%67%92%90%83%0.3White0%83%33%80%57%0.03Disease duration (days)^a^12138315542.50.2Polyarthritis0%50%67%80%63%0.18Number of active joints^a^1.04.55.05.54.00.28ESR \>3x ULN100%67%91%43%73%0.27CRP \>3x ULN100%83%91%40%79%0.28Ferritin (ng/mL)^a^12,8741,3941,0626277830.09CHAQ score^a^0.91.31.90.81.40.6Pain score (0--10)^a^36.567.560.6Physician global assessment (0--10)^a^47555.50.12Parent global assessment well-being (0--10)^a^076660.103Initiated GC at baseline100%100%42%70%67%0.029Initial GC dose (mg/kg)^a^0.670.970.000.680.800.548GC prior to baseline50%16.7%8.3%30%20%0.350Initial dose of each CTP medication in mg/kg (IQR)^a^0.67 (0.6--0.73)0.487 (0.46--0.64)2.93 (2--3.6)^b^8.14 (8--12)Not Applicable^a^Median^b^Anakinra dose (anakinra was used as the initial IL-1i in all patients)

Five patients were taking GC prior to starting their respective CTP (median 12 days prior to baseline): of these patients, three patients started on IL6i, and one each started on IL1i and MTX. One patient started on the IL1i CTP was lost to follow-up after the baseline visit.

Figure [1](#Fig1){ref-type="fig"} shows the number of children in each CTP group that eventually switched CTPs or added a DMARD such as methotrexate. Ultimately, 12 of 30 children (40%) switched from their original CTP or added methotrexate. Figure [2](#Fig2){ref-type="fig"} shows initial CTP choice by site. Sites 1--4 exclusively used non-biologic CTPs to start, while sites 6--13 exclusively used biologic CTPs, with site 5 the only site to start both biologic and non-biologic CTPs. Although the majority of sites enrolled few patients (1 to 3), reasons for selecting a particular CTP varied mostly by site rather than CTP. The most common reasons cited were: "treatment works best" in 19/29 (65.5%) (GC, IL1i, IL6i CTPs); "treatment is safer" in 15/29 (51.7%) (MTX, IL1i, IL6i); "treatment is better tolerated" in 14/29 (48.3%) (MTX, IL1i, IL6i); and "always select(s) this treatment" in 10/29 (34.5%) (GC, IL1i, IL6i).Fig. 1Initial Consensus Treatment Plan (CTP) Choices and Subsequent Treatment Changes. The total numbers of patients started on each CTP are shown, along with those remaining on the original CTP medication (*dark blue*), switching to a different CTP (*green*) or adding another CTP medication (*light blue*). IL1i: IL1 inhibitor; IL6i: IL6 inhibitor Fig. 2Initial Consensus Treatment Plan (CTP) Choice By Site. CTP choices distributed by site, showing that 4 sites started only a non-biologic CTP (*red colors*), while 8 sites started only a biologic CTP (*blue colors*), IL1i: IL1 inhibitor; IL6i: IL6 inhibitor

Owing to the reliance on data collection at regular office visits, there was variability in the designated 9 month visit dates with the median being 39.9 weeks after baseline (IQR: 37.3, 43.4, range 29.9--54.7 weeks) Three children did not have a 9 month visit (1 GC and 2 IL1i CTP patients); of these, 1 of the 2 IL1i treated patients and the GC treated patient were lost to follow-up.

While feasibility of the study methodology rather than clinical outcomes was the major purpose of this study, and with the caveat that no attempt was made to adjust for patient characteristics between these very small groups, differences between non-biologic and biologic CTPs were nevertheless observed. The primary endpoint of CID off GC at 9 months was achieved by 50% of biologic CTP initiated children (11 of the 22 children), whereas none of the eight non-biologic CTP initiated children achieved this endpoint (*p* = 0.014) (Table [2](#Tab2){ref-type="table"}).Table 2Achievement of Clinical Inactive Disease (CID) off Glucocorticoids (GC) in Non-Biologic and Biologic initiated patients (primary endpoint), as well as in the 4 Consensus Treatment Plan (CTP) groupsBiologic groupingPatient Status at Month 9Total *N* = 30Gluco-corticoids *N* = 2Methotrex-ate *N* = 6IL1i^a^ *N* = 12IL6i^a^ *N* = 10*p*-valueNon-Biologic CTP *N* = 8Biologic CTP *N* = 22*p*-valueCID13/30 (43.3%)0/22/6 (33.3%)5/12 (41.7%)6/10 (60.0%)0.5492/8 (25.0%)11/22 (50.0%)0.407Off GC20/30 (66.7%)1/2 (50.0%)1/6 (16.7%)10/12 (83.3%)8/10 (80.0%)0.0192/8 (25.0%)18/22 (81.8%)0.007CID off GC11/30 (36.7%)0/20/65/12 (41.7%)6/10 (60.0%)0.0790/811/22 (50.0%)0.014CID off GC and no CTP change8/30 (26.7%)0/20/63/12 (25.0%)5/10 (50.0%)0.1680/88/22 (36.4%)0.071Also shown are all patients who achieved CID (regardless of GC), all patients who were off GC, and all patients who achieved CID off GC and did not change their CTP treatments, at 9 months. Patients lost to follow-up were considered treatment failures^a^IL1i: IL-1 inhibitor; IL6i: IL-6 inhibitor

This failure to achieve CID off GC was not simply due to slow tapering of GC: 6 of 8 (75%) children started on non-biologic CTPs had active disease at 9 months compared with 9 of 22 (41%) of children started on biologic CTPs (*p* = 0.407); and 6 of 8 (75%) of non-biologic CTP treated children were still taking GC at 9 months, compared to 4 of 22 (18%) of biologic CTP treated children (*p* = 0.007). Table [3](#Tab3){ref-type="table"} also shows the primary endpoint analysis by individual CTP group, as well as of patients who achieved the endpoint without switching/adding CTP medications. Likely due to the small numbers in each group, statistical significance was not achieved in these groups. All but one provider generally followed the CTP GC tapering recommendations, so that if by Month 3, if GC were not tapered to less than 50% of the initial dose, treatment was intensified or the CTP was changed. There was no significant difference in the median number of days from baseline of the 9 month visit between the biologic (282 days) and non-biologic (271 days) CTP groups (*p* = 0.599), despite the variability in the 9 month visit date discussed above.Table 3Adverse events reported in all patients by CTP at time of eventCTP at time of AEGCMTXIL-1 InhibitorIL-6 InhibitorTotalGrade 202 (allergic reaction \[1\], arthritis flare \[1\])5 (MAS \[1\], hepatitis \[1\], rash \[1\], Strep pharyngitis \[1\], injection site reaction \[1\])8 (fever \[1}, rash \[1\], arthritis flare \[2\], headache \[1\], neutropenia \[1\], viral illness \[1\], infusion reaction \[1\])15Grade 3002 (infections)^b^02Grade 40001 (infusion reaction)1SAE01^a^2 (infections)^b^1 (MAS)3^a^Appendicitis and appendectomy^b^1 varicella (anakinra), 1 cellullitis (canakinumab)

Adverse events are listed in Table [3](#Tab3){ref-type="table"}. There was one Grade 4 AE infusion reaction with tocilizumab. There were 4 SAE's: 2 that resulted in hospitalization for intravenous antimicrobial therapy (cellulitis in a child taking canakinumab and GC \[Grade 3\] and varicella in a child taking anakinra \[Grade 3\]), 1 hospitalization for appendicitis and appendectomy on methotrexate and GC, and 1 for macrophage activation syndrome (MAS) in a child on tocilizumab (Grade 3). One additional child who was receiving anakinra developed MAS and was treated with oral prednisone without hospitalization (Grade 2). All patients recovered uneventfully.

Discussion {#Sec4}
==========

This pilot study assessed the feasibility of using standardized CARRA CTPs for untreated systemic JIA, 90% of whom had disease onset less than 4 months prior to treatment, to evaluate the comparative effectiveness of commonly used treatment approaches. Importantly, the study established that the CARRA Registry and the coordinating center at the Duke Clinical Research Institute (DCRI) could effectively operationalize and capture the data for such a study, but it also demonstrated that better methods to decrease missing visits and data, and to be able to capture clinical data between visits for the larger study were needed. Interestingly, each plan was used with similar frequency aside from the GC-only plan, confirming community equipoise on treatment selection. The choice of plan varied by site/individual physician rather than disease characteristics of the individual child, with the caveat that at most a few patients were treated at each site. However, plan choice driven by site allows for a "pseudo-block randomization" in the context of a larger observational comparative effectiveness study. The distribution of CTP usage followed results of surveys conducted as part of the development of the original CTPs \[[@CR17]\], indicating that there continues to be substantial variability in physician practice with regard to initial treatment choices for systemic JIA.

The results of this pilot study underline the need for a larger definitive comparative effectiveness study assessing all 4 CTPs. The quandary about the safest and most effective treatment of new-onset systemic JIA has been informed by studies of the IL1i anakinra (recombinant IL-1 receptor antagonist). Recent studies looking at early use of anakinra in systemic JIA demonstrated a marked reduction in the development of chronic persistent arthritis from a historical rate of 50--60% to less than 10% \[[@CR9], [@CR11]\], a rate of response markedly distinct from that observed in a randomized controlled trial of anakinra in established chronic systemic JIA \[[@CR2]\]. These studies raise the possibility of a "window of opportunity" in early systemic JIA during which cytokine blockade could be especially effective \[[@CR23]\]. Even though this pilot study included small numbers of children who were followed for only 9 months, the results indicate that untreated systemic JIA patients started on IL-1i or IL-6i biologics achieved the primary endpoint (CID off GC at 9 months) more frequently than children not started on a biologic. Children treated with non-biologic CTPs were more likely to both have continued active disease and continue to be treated with GC compared to those treated with biologic CTPs. Whether this will hold true in a larger population of children followed for a longer period of time remains to be seen, as no attempt was made to correct for baseline clinical features or other potentially confounding variables, rendering the conclusions of this this pilot study far from definitive \[[@CR19]\].

Study limitations include the observational design. As noted, no adjustments were made to address confounding by indication (prescriber channeling). The basic CTP approach assumes that treatment choice is determined by physician preferences rather than patient disease characteristics, and further assumes that individual physicians influence disease outcomes only through the CTP choice. We observed evidence in favor of the first assumption in this pilot study, but the latter assumption is difficult to assess given the strong correlations between physician and treatment choice. Missing data points and visits outside of the suggested visit schedule were relatively common, limiting analysis of the results. Children were sometimes started on medications, especially GC, prior to starting the CTP. Short-term use of GC was allowed, which may have changed the baseline disease characteristics of these patients. However, prior treatment with GC is particularly difficult to avoid at presentation of new onset systemic JIA, a phase of the disease in which children are often acutely ill; excluding these children could eliminate significant numbers of children, particularly the sickest children. In addition, patients were followed for a relatively short period of time (9 months), with CID assessed at a single time point that may incompletely reflect the treatment response in this dynamic disease. Evaluation of stably inactive disease, such as clinical inactive disease for 6 consecutive months (i.e., clinical remission) and clinical inactive disease for 12 consecutive months off of all medications (i.e., clinical remission off medication) \[[@CR21]\] will be assessed in the larger CTP study informed by this pilot, but was not able to be captured in this study. Data collection through the CARRA Registry will allow assessment of long-term outcomes for decade or more after Registry enrollment, including outcomes such as medication safety and functional status as well as remission. Lastly, the small sample size, differences in the demographics of the study cohort compared to other systemic JIA cohorts, the short follow-up duration and missing data limit the external validity of the results of this pilot study.

The use of modified ILAR criteria for diagnosis may affect the generalizability of the study results. It is recognized that many children with systemic JIA in the earliest stages of disease require treatment, yet may not strictly fulfill ILAR criteria (especially the requirement for 6 weeks of arthritis) \[[@CR24]\]. Indeed, the Yamaguchi criteria for Adult Onset Still Disease (the adult correlate of systemic JIA) does not require overt arthritis for diagnosis \[[@CR25], [@CR26]\]. It is possible that use of these modified criteria by clinicians other than experienced pediatric rheumatologists may lead to misdiagnosis. We emphasize that it is critical to exclude other diagnoses that may be mistaken for systemic JIA, such as infection, malignancy (in particular acute lymphoblastic leukemia, lymphoma and neuroblastoma) or genetic auto-inflammatory diseases prior to starting treatment for systemic JIA using the CTPs, especially before treatment with GC. In cases where the diagnosis is not based on the triad of characteristic fever, rash and arthritis, the advice of an expert pediatric rheumatologist should be sought.

The larger comparative effectiveness study, implementing the systemic JIA CTP study at 60 or more CARRA Registry sites, will retain the observational study design including non-randomization of treatment allocation. This study, termed the FiRst-line Options in Systemic JIA Treatment (FROST), will address limitations recognized in the pilot study including reducing important potential biases such as confounding by indication by using propensity scoring, as well as instrumental variable and marginal structural model analyses. Bayesian analytic methods will also be utilized for the larger study. Bayesian prior belief exercises needed for the analyses were conducted at a recent CARRA annual meeting. This pilot study was employed to inform the power calculations for FROST, in which we plan to use an intention-to-treat analytic approach (see Additional files [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}). Aggressive efforts to improve data quality are planned, including more rigorous site education and awareness, leveraging various forms of communication. More detailed information about GC use prior to and during treatment will be obtained and analyzed. Children/parents will be queried about symptoms and GC dose on a regular basis using home electronic mobile device reporting. We will collect detailed information about SAEs and important medical events (IME) throughout the CTP study (including MedDRA coding of events). Lastly, important long-term follow up of children started on the CARRA systemic JIA CTPs will be accomplished using existing CARRA Registry infrastructure to follow all enrolled patients for 10 or more years, including use of a call center to contact patients and their families if the child transitions from pediatric to adult care or moves to a non-participating center.

We observed a few unexpected patient characteristics in this small pilot study, such as a female predominance, whereas most large studies of systemic JIA have reported a nearly equal female to male ratio \[[@CR8], [@CR9]\]. There were also patients with longer than expected disease duration prior to study enrollment. These differences are anticipated to be minimized by the inclusion of many more patients into the larger FROST CTP study.

Conclusions {#Sec5}
===========

This pilot study of the four CARRA standardized CTPs for untreated mostly new-onset systemic JIA successfully demonstrated the feasibility of their implementation in a larger observational comparative effectiveness study using the CARRA Registry for data collection. FROST, the planned follow-on larger, longitudinal study will establish whether biologic medications started early in the disease course will result in better outcomes for children with new onset systemic JIA.
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